Literature DB >> 1695348

Occurrence of atrial fibrillation in patients with paroxysmal supraventricular tachycardia due to atrioventricular nodal reentry.

J L Hurwitz1, L D German, D L Packer, J M Wharton, E A McCarthy, W E Wilkinson, E N Prystowsky, E L Pritchett.   

Abstract

The occurrence of atrial fibrillation in patients with paroxysmal supraventricular tachycardia (PSVT) has been well documented when PSVT is secondary to atrioventricular reentry, but not when PSVT is secondary to atrioventricular nodal reentry (AVNRT). Seventeen patients with AVNRT were followed using transtelephonic electrocardiogram monitoring to document symptomatic tachycardias. The median length of telephone monitor surveillance was 357 days. Fifteen of 17 patients transmitted electrocardiograms that showed PSVT. Three of 17 patients (18%) transmitted electrocardiograms that showed atrial fibrillation. A transition from PSVT into atrial fibrillation was not recorded, but all three did have PSVT recorded on other days of follow-up. We report the occurrence of atrial fibrillation in patients with AVNRT and that its incidence is higher than expected for the general population.

Entities:  

Mesh:

Year:  1990        PMID: 1695348     DOI: 10.1111/j.1540-8159.1990.tb02094.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  7 in total

1.  Atrioventricular nodal reentrant tachycardia with paroxysmal atrial fibrillation: clinical and electrophysiological features and predictors of atrial fibrillation recurrence following elimination of atrioventricular nodal reentrant tachycardia.

Authors:  Basri Amasyali; Sedat Kose; Kudret Aytemir; Ayhan Kilic; Gulumser Heper; Hurkan Kursaklioglu; Atila Iyisoy; Turgay Celik; E Bariş Kaya; Ersoy Isik
Journal:  J Interv Card Electrophysiol       Date:  2005-09       Impact factor: 1.900

2.  Clinical and electrophysiological characteristics of the patients with relatively slow atrioventricular nodal reentrant tachycardia.

Authors:  Harun Evrengul; Yusuf I Alihanoglu; I Dogu Kilic; Bekir S Yildiz; Sedat Kose
Journal:  J Interv Card Electrophysiol       Date:  2014-05-06       Impact factor: 1.900

3.  Common and rare variants in SCN10A modulate the risk of atrial fibrillation.

Authors:  Javad Jabbari; Morten S Olesen; Lei Yuan; Jonas B Nielsen; Bo Liang; Vincenzo Macri; Ingrid E Christophersen; Nikolaj Nielsen; Ahmad Sajadieh; Patrick T Ellinor; Morten Grunnet; Stig Haunsø; Anders G Holst; Jesper H Svendsen; Thomas Jespersen
Journal:  Circ Cardiovasc Genet       Date:  2015-02

4.  P wave dispersion predicts recurrence of paroxysmal atrial fibrillation in patients with atrioventricular nodal reentrant tachycardia treated with radiofrequency catheter ablation.

Authors:  Basri Amasyali; Sedat Kose; Kudret Aytemir; Ayhan Kilic; Hasan Turhan; Turgay Celik; Hurkan Kursaklioglu; Atila Iyisoy; Cengiz Ozturk; Ersoy Isik
Journal:  Ann Noninvasive Electrocardiol       Date:  2006-07       Impact factor: 1.468

5.  Assessment of the neutrophil/lymphocyte ratio in patients with supraventricular tachycardia.

Authors:  Mesut Aydın; Abdülkadir Yıldız; Murat Yüksel; Nihat Polat; Adem Aktan; Yahya İslamoğlu
Journal:  Anatol J Cardiol       Date:  2016-01       Impact factor: 1.596

6.  Paroxysmal supraventricular tachycardia and risk of ischemic stroke: A systematic review and meta-analysis.

Authors:  Pongprueth Rujirachun; Phuuwadith Wattanachayakul; Arjbordin Winijkul; Patompong Ungprasert
Journal:  J Arrhythm       Date:  2019-05-14

7.  Management and outcomes of atrial fibrillation in 241 healthy children and young adults: Revisiting "lone" atrial fibrillation-A multi-institutional PACES collaborative study.

Authors:  Iqbal El Assaad; Benjamin H Hammond; Lukas D Kost; Sarah Worley; Christopher M Janson; Elizabeth D Sherwin; Elizabeth A Stephenson; Christopher L Johnsrude; Mary Niu; Ira Shetty; David Lawrence; Anthony C McCanta; Seshadri Balaji; Shubhayan Sanatani; Frank Fish; Gregory Webster; Peter F Aziz
Journal:  Heart Rhythm       Date:  2021-07-31       Impact factor: 6.779

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.